A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Phase 1
52
about 2.8 years
18+
6 sites in CA, CO, IL +2
About this study
Researchers are testing if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates. The trial will last for 1024 days and involve approximately 52 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take bulumtatug fuvedotin
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Objective Response Rate
Secondary: Clinical benefit rate, Disease control rate, Duration of response, Half-life (t1/2), Immunogenicity, Incidence, rate and severity of treatment-emergent adverse events., Maximum Concentration (Cmax), Overall survival
Oncology